ReviewDiscover oncology2025
Microbiome landscapes of the bladder, intestine, and vagina in bladder cancer: a systematic review.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gut microbiotas attributed to disorders and diseases of the gastrointestinal tract, colorectal cancer, bladder cancer: Geographical factors, inflammation, metabolic toxic.World journal of gastrointestinal pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicrobiomes have been linked to oncogenesis, e.g. the intestinal microbiome and colon cancer or HPV-associated cervical cancer. A connection between microbiomes of different body cavities and tumor oncogenesis was shown. The gut microbiome's influence on bladder cancer was established, raising the question whether nearby microbiomes (rectum, vagina) also influence bladder cancer due to their proximity.
objectiveConsidering the influence of various body cavities and the broader microbial components, this systematic review aims to investigate differences in the bladder, vaginal, and intestinal microbiota-including bacterial, viral, fungal and archaea-between patients with bladder cancer and healthy controls.
methodsDatabases (PubMed, Scopus, Embase) were searched until April 2022. Three types of studies were included: "(1) studies using bladder cancer and control groups (case-controlled studies) (2) studies that provided information on the presence or abundance of microbial taxa (3) studies that provided information on increased or decreased taxa in bladder cancer and/or control groups.". Risk of bias was assessed using the Newcastle Ottawa Scale.
resultsFourteen studies (695 samples: 403 bladder cancer, 292 controls) were analyzed. Bacterial taxa that have been detected in at least two studies, the genera Geobacillus and Rubrobacter were more frequently in bladder cancer patients; while Streptococcus and Roseomonas were more prevalent in controls. No consistent taxa were identified across stool or bladder tissue samples.
conclusionThe microbiota in bladder cancer patients show significant variation across studies. Standardized methods and expanded investigations into viral and fungal components are needed to clarify the role of microbiota in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.